Skip to content

Author

A. Drilon

We have 4 of 723 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib.

BACKGROUND All targeted therapies approved for ROS1-fusion-positive non-small cell lung cancer (NSCLC) are type I inhibitors. These TKIs may induce resistance amenable to type II inhibition. Cabozantinib is a type II ROS1/MET tyrosine kinase inhibitor with preclinical activity against on-target ROS1 resistance mutation...

J. Rubio-Perez, M. Repetto, Ling-Feng Ye et al. · 0 citations
Review Open access Oct 2026

Results from a multisite quality improvement initiative in solid tumor precision medicine.

582 Background: Timely, comprehensive biomarker testing is essential to identify actionable genomic alterations and guide targeted therapy in patients with advanced solid tumors. However, community and academic cancer centers often encounter delays in ordering, prolonged turnaround from diagnosis to results, an...

Amany R. Keruakous, W. Waugh, Samuel K. Caughron et al. · 0 citations
Aug 2026

The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.

SMARCA4 alteration class and allelic status define biologically and clinically distinct subsets of tumors and support incorporating allelic status and functional mutation class into patient selection strategies for emerging BRM-targeted therapies.

M. Repetto, M. Gormally, Jason Chang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.